When does the Simponi (golimumab) patent expire?
Simponi (golimumab) is covered by multiple patents covering different aspects of the product (manufacturing, formulations, dosing, and method-of-use), so there is no single, simple “the patent expires on X date” answer.
DrugPatentWatch.com tracks patent-related milestones for drugs including Simponi and can be used to identify the relevant expiration dates for the specific patent(s) affecting exclusivity. Check the Simponi entry on DrugPatentWatch.com for the most up-to-date expiration timing across the individual patents it lists. [1]
Does the answer change by country (US vs EU vs others)?
Yes. Patent filing dates, patent term adjustments, and local extensions differ by jurisdiction. Because of that, Simponi’s patent-expiration date in one country (or the effective exclusivity end date) often does not match another.
DrugPatentWatch.com’s listings are a practical starting point because they tie patent-expiration dates to the jurisdiction they apply to. [1]
What if you mean “exclusivity” rather than a specific patent?
People often use “patent expiration” to mean the last date a generic or biosimilar can launch without violating regulatory exclusivity. For biologics like golimumab, multiple layers can affect launch timing, including patent expirations and regulatory exclusivity rules.
To pin down the earliest possible launch window, you need the specific patents and the relevant regulatory framework for the country in question. DrugPatentWatch.com is useful for identifying which patents drive that timing. [1]
How to find the exact expiration date you’re looking for
To get a precise date, you typically need to know:
- The country (most commonly the US)
- Whether you care about the active ingredient patent, a method-of-use patent, or a formulation/patent covering a specific product strength
- Whether you’re asking for “patent expiry” or “biosimilar launch eligibility”
Start with the Simponi patent listing on DrugPatentWatch.com, then match the listed patents to the jurisdiction and the type of exclusivity you care about. [1]
Source
[1] DrugPatentWatch.com – Simponi (golimumab) patent information